743 related articles for article (PubMed ID: 24399234)
1. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate disease activity or disease remission during the first year after diagnosis: data from the ESPOIR cohort.
Combe B; Logeart I; Belkacemi MC; Dadoun S; Schaeverbeke T; Daurès JP; Dougados M
Ann Rheum Dis; 2015 Apr; 74(4):724-9. PubMed ID: 24399234
[TBL] [Abstract][Full Text] [Related]
2. Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.
Vermeer M; Kuper HH; Hoekstra M; Haagsma CJ; Posthumus MD; Brus HL; van Riel PL; van de Laar MA
Arthritis Rheum; 2011 Oct; 63(10):2865-72. PubMed ID: 21647867
[TBL] [Abstract][Full Text] [Related]
3. Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort.
Combe B; Rincheval N; Benessiano J; Berenbaum F; Cantagrel A; Daurès JP; Dougados M; Fardellone P; Fautrel B; Flipo RM; Goupille P; Guillemin F; Le Loët X; Logeart I; Mariette X; Meyer O; Ravaud P; Saraux A; Schaeverbeke T; Sibilia J
J Rheumatol; 2013 Oct; 40(10):1650-7. PubMed ID: 23950185
[TBL] [Abstract][Full Text] [Related]
4. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study.
Mancarella L; Bobbio-Pallavicini F; Ceccarelli F; Falappone PC; Ferrante A; Malesci D; Massara A; Nacci F; Secchi ME; Manganelli S; Salaffi F; Bambara ML; Bombardieri S; Cutolo M; Ferri C; Galeazzi M; Gerli R; Giacomelli R; Grassi W; Lapadula G; Cerinic MM; Montecucco C; Trotta F; Triolo G; Valentini G; Valesini G; Ferraccioli GF;
J Rheumatol; 2007 Aug; 34(8):1670-3. PubMed ID: 17611987
[TBL] [Abstract][Full Text] [Related]
5. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
Hyrich KL; Watson KD; Silman AJ; Symmons DP;
Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
[TBL] [Abstract][Full Text] [Related]
6. Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints.
Aletaha D; Smolen JS
Arthritis Rheum; 2011 Dec; 63(12):3702-11. PubMed ID: 21953215
[TBL] [Abstract][Full Text] [Related]
7. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
8. Joint damage progression in patients with rheumatoid arthritis in clinical remission: do biologics perform better than synthetic antirheumatic drugs?
Ciubotariu E; Gabay C; Finckh A;
J Rheumatol; 2014 Aug; 41(8):1576-82. PubMed ID: 25028383
[TBL] [Abstract][Full Text] [Related]
9. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA.
Keystone E; Freundlich B; Schiff M; Li J; Hooper M
J Rheumatol; 2009 Mar; 36(3):522-31. PubMed ID: 19228659
[TBL] [Abstract][Full Text] [Related]
10. Remission and radiographic outcome in rheumatoid arthritis: application of the 2011 ACR/EULAR remission criteria in an observational cohort.
Lillegraven S; Prince FH; Shadick NA; Bykerk VP; Lu B; Frits ML; Iannaccone CK; Kvien TK; Haavardsholm EA; Weinblatt ME; Solomon DH
Ann Rheum Dis; 2012 May; 71(5):681-6. PubMed ID: 21994234
[TBL] [Abstract][Full Text] [Related]
11. Physician global assessment at 3 months is strongly predictive of remission at 12 months in early rheumatoid arthritis: results from the CATCH cohort.
Choy T; Bykerk VP; Boire G; Haraoui BP; Hitchon C; Thorne C; Keystone EC; Pope JE;
Rheumatology (Oxford); 2014 Mar; 53(3):482-90. PubMed ID: 24241035
[TBL] [Abstract][Full Text] [Related]
12. Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort.
Lukas C; Mary J; Debandt M; Daïen C; Morel J; Cantagrel A; Fautrel B; Combe B
Arthritis Res Ther; 2019 Nov; 21(1):243. PubMed ID: 31730497
[TBL] [Abstract][Full Text] [Related]
13. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden early arthritis clinic and ESPOIR cohorts.
van Nies JA; Tsonaka R; Gaujoux-Viala C; Fautrel B; van der Helm-van Mil AH
Ann Rheum Dis; 2015 May; 74(5):806-12. PubMed ID: 25561360
[TBL] [Abstract][Full Text] [Related]
14. Comparison of long-term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicity.
Krieckaert CL; Jamnitski A; Nurmohamed MT; Kostense PJ; Boers M; Wolbink G
Arthritis Rheum; 2012 Dec; 64(12):3850-5. PubMed ID: 22933315
[TBL] [Abstract][Full Text] [Related]
15. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register.
Kristensen LE; Kapetanovic MC; Gülfe A; Söderlin M; Saxne T; Geborek P
Rheumatology (Oxford); 2008 Apr; 47(4):495-9. PubMed ID: 18316338
[TBL] [Abstract][Full Text] [Related]
16. Sustained Remission Improves Physical Function in Patients with Established Rheumatoid Arthritis, and Should Be a Treatment Goal: A Prospective Observational Cohort Study from Southern Sweden.
Einarsson JT; Geborek P; Saxne T; Kristensen LE; Kapetanovic MC
J Rheumatol; 2016 Jun; 43(6):1017-23. PubMed ID: 27036384
[TBL] [Abstract][Full Text] [Related]
17. Determinants of reaching drug-free remission in patients with early rheumatoid or undifferentiated arthritis after one year of remission-steered treatment.
Wevers-de Boer KV; Heimans L; Visser K; Schouffoer AA; Molenaar ET; van Groenendael JH; Peeters AJ; Speyer I; Collée G; Huizinga TW; Allaart CF
Rheumatology (Oxford); 2015 Aug; 54(8):1380-4. PubMed ID: 25687553
[TBL] [Abstract][Full Text] [Related]
18. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data.
Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM
Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499
[TBL] [Abstract][Full Text] [Related]
19. Modern treatment strategies in rheumatoid arthritis.
Hetland ML
Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
[TBL] [Abstract][Full Text] [Related]
20. Absent "Window of Opportunity" in smokers with short disease duration. Data from BARFOT, a multicenter study of early rheumatoid arthritis.
Söderlin MK; Bergman S;
J Rheumatol; 2011 Oct; 38(10):2160-8. PubMed ID: 21807778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
